Enterprise Associates 12, L... Net Worth

The estimated Net Worth of Enterprise Associates 12, L... is at least $36 Million dollars as of 10 December 2014. Enterprise L owns over 1,000,000 units of Trevena Inc stock worth over $36,039,566 and over the last 11 years Enterprise sold TRVN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Enterprise L TRVN stock SEC Form 4 insiders trading

Enterprise has made over 3 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Enterprise bought 1,000,000 units of TRVN stock worth $4,000,000 on 10 December 2014.

The largest trade Enterprise's ever made was buying 1,000,000 units of Trevena Inc stock on 10 December 2014 worth over $4,000,000. On average, Enterprise trades about 495,713 units every 77 days since 2014. As of 10 December 2014 Enterprise still owns at least 4,811,691 units of Trevena Inc stock.

You can see the complete history of Enterprise L stock trades at the bottom of the page.

Insiders trading at Trevena Inc

Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, and Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.

What does Trevena Inc do?

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Complete history of Enterprise L stock trades at Ardelyx Inc and Trevena Inc

Trevena Inc executives and stock owners

Trevena Inc executives and other stock owners filed with the SEC include:

• Maxine Gowen,
  Director
• Carrie Bourdow,
  President, Chief Executive Officer, Director
• Carrie L. Bourdow,
  Pres, CEO & Director
• Mark Demitrack,
  Senior Vice President and Chief Medical Officer
• Dr. Mark A. Demitrack,
  Sr. VP & Chief Medical Officer
• Robert Yoder,
  Senior Vice President and Chief Business Officer
• Dan Ferry,
  IR Contact Officer
• Scott Applebaum,
  Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs
• Barbara Yanni,
  Independent Director
• Anne Phillips,
  Independent Director
• Jake Nunn,
  Independent Director
• Julie McHugh,
  Independent Director
• Michael Dougherty,
  Independent Director
• Scott Braunstein,
  Independent Director
• Barry Shin,
  Chief Financial Officer, Senior Vice President
• Leon Moulder,
  Independent Chairman of the Board
• Patricia M. Drake,
  Chief Commercial Officer
• Robert T. Yoder,
  Sr. VP, Chief Bus. Officer & Head of Commercial Operations
• Barry Shin,
  Sr. VP & CFO
• Michael Catalano,
  VP of Marketing
• Dr. Howard A. Rockman M.D.,
  Scientific Founder, Consultant and Member of Scientific Advisory Board
• John P. Hamill,
  VP Fin,Princ Fin&Acct Officer
• Marvin Johnson,
  Director
• Michael W. Lark,
  Sr. VP, Research & CSO
• Jason Raleigh Nunn,
  Director
• Adam Koppel,
  Director
• Yacoub Habib,
  SVP, Bus Dev & Corp Planning
• Roberto Cuca,
  Sr. VP and CFO
• David Soergel,
  Sr. VP, Clinical Development
• John M Limongelli,
  Sr. VP,General Counsel & Secy
• Jonathan Violin,
  SVP-Scientific Affairs & IR
• David Geoghegan,
  Sr. VP, Operations
• Partners Viii, L.P.Alta Par...,
  
• Francois Nader,
  Director
• Venture Management Co. V, L...,
  
• Farah Champsi,
  Director
• Robert Prachar,
  Sr. VP, Corp. Strategy
• David F Solomon,
  Director
• Rosamond Deegan,
  Sr VP, Bus Dev & Operations
• Laboratories Holdings Ltd F...,
  
• Terrance Mcguire,
  Director
• Ventures Viii, L.P.Cavanaug...,
  
• Venture Management Co. V, L...,
  
• Patricia M. Drake,
  SVP, Chief Commercial Officer
• Mark Corrigan,
  Director